Topic: Teva Pharmaceutical Industries Ltd.

Diversified healthcare giant Novartis (NYSE:NVS) reported impressive 2011 results in January 2012. These strong trends are not projected to carry...

2 Stocks to Beat a Recession

With the Dow well above the 12,000 mark again but the threat of a double-dip recession still present, it would do investors well to consider the...
Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA)'s stock had its "neutral" rating reaffirmed by equities research analysts at Goldman Sachs (NYSE:...
Investment analysts at Goldman Sachs (NYSE: GS) raised their price target on shares of Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) to $48.00...
The Company to Host Investigator Panel and Reception to Review Clinical Data and Development Program. OncoGenex Pharmaceuticals, Inc. (NASDAQ:...
ChromaDex Corporation (OTCBB:CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to...

Don't Sell on This News

Seattle Genetics (Nasdaq: SGEN ) fell quite a bit after the company announced a change to the warnings section of the label for its blood cancer...
Teva Pharmaceuticals (TEVA) has not been the best performer in my portfolio since I added a position in the stock during the third quarter of 2011...
Equities research analysts at Barclays Capital (NYSE: BCS) initiated coverage on shares of Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) in a...
Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA)'s stock had its "buy" rating reaffirmed by equities research analysts at Deutsche Bank (NYSE: DB)...